Biotech | May 12, 2022
First patient dosed with antiepileptic drug candidate CB03 in a first-in-human Phase I trial
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
Takeda and United Nations Global Compact Network of India (UNGCNI) join hands
In the UK, Bartec has been synonymous with Mediso products for 18 years, proof of a successful partnership
The study, presented at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated with poorer neurological recovery from ischaemic stroke both in the acute phase (24 hours) and after three months
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
Center of Excellence for Molecular Diagnostics and Proteomics will enable affordable diagnostics for infectious diseases in India
Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo
It is expanding the diagnostics business footprint in North East India
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Subscribe To Our Newsletter & Stay Updated
